Chemsex Engagement and HIV Biomedical Prevention in MSM

Recruiting

• Conditions: Recreational Drug Use
• Interventions: Diagnostic Test: HIV test

• Registration Number: NCT05031832
• Lead Sponsor: Chinese University of Hong Kong

Brief Summary

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-01
• Study First Submitted: 2021-08-30
• Study First Submitted QC: 2021-08-30
• Study First Posted: 2021-09-02
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-19
• Last Update Posted: 2024-08-21
• Primary Completion: 2024-09-30
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 1000

Inclusion Criteria

• aged 18 or above
• male
• have had sex with men since 2019
• could be communicated in English or Chinese

Read More

Exclusion Criteria

• failed to provide consent

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HIV-negative	HIV test	-

Primary Outcome Measures

Name	Time	Method
pre-exposure prophylaxis coverage	6 months	proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire
Good antiretroviral therapy adherence	2 years	proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire
Drug use pattern	6 months	types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire

Trial Locations

Locations (1)

The Chinese University of Hong Kong; 🇭🇰 Hong Kong, Hong Kong, China, Hong Kong